Isarna Announces Orphan Drug Designation in the European Union for ISTH0036 to Treat Advanced-Stage Glaucoma

26-May-2015 - Germany

Isarna Therapeutics announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation for ISTH0036, a locked nucleic acid-modified antisense oligonucleotide, for the prevention of scarring post filtration surgery in glaucoma. With EMA Orphan Drug Designation, Isarna is eligible for development fee reductions and incentives including 10-year market exclusivity for ISTH0036.

“Orphan designation for ISTH0036 in the European Union (EU) is a substantial accomplishment and corporate milestone for Isarna,” said Dr. Philippe Calais, President and Chief Executive Officer of Isarna Therapeutics. “Currently, patients with advanced-stage glaucoma have limited long-term treatment options. The EMA’s recognition of the potential of ISTH0036 to help protect glaucoma patients’ vision in this stage of their disease with orphan drug status is a significant step forward for the ongoing development of this novel therapy.”

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...